Crinetics Pharmaceuticals, Inc.
CRNX
Rank in Stocks
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Share Price
$84.95
Last synced: 2026-09-01
Market Cap
$9.00B
Change (1 day)
0.00%
Change (1 year)
98.25%
Country
US
Trade Crinetics Pharmaceuticals, Inc. (CRNX)
Category
Healthcare
Revenue for Crinetics Pharmaceuticals, Inc. (CRNX)
Revenue in Jun 2026 TTM: $42.16M
According to Crinetics Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is $42.16M. In 2023 the company made a revenue of $4.01M a decrease compared to the revenue in the year 2022 that was $4.74M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Crinetics Pharmaceuticals, Inc. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $42.16M | 3,957.36% |
| 2024 | $1.04M | -74.11% |
| 2023 | $4.01M | -15.28% |
| 2022 | $4.74M | 339.42% |
| 2021 | $1.08M | 1,418.31% |
| 2020 | $71.00K | -94.05% |
| 2019 | $1.19M | -50.86% |
| 2018 | $2.43M | 18.73% |
| 2017 | $2.05M | 247.20% |
| 2016 | $589.00K | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 29,846.63% |
US
|
|
| $2.23B | 5,185.13% |
US
|
|
| $15.74B | 37,247.77% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 14,183.35% |
NL
|
